From targets to targeted therapies and molecular profiling in non-small cell lung carcinoma

Annals of Oncology

Volumn 24, Issue 3, 2013, Pages 577-585

  Thomas, A ^a   Rajan, A ^a   Lopez Chavez, A ^b   Wang, Y ^a   Giaccone, G ^a  

^a University Cancer Institute   (United States)

^b OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

Molecular profiling; Next generation sequencing; Non small cell lung cancer; Tumor heterogeneity

Indexed keywords

1 (1 CYANO 1 METHYLETHYL) 3 METHYL 8 (3 QUINOLINYL)IMIDAZO[4,5 C]QUINOLIN 2(1H,3H) ONE; 4 DIALLYLAMINOMETHYLENE 1,3,4,7,10,11,12,13,14,15,16,17 DODECAHYDRO 6 HYDROXY 1 METHOXYMETHYL 10,13 DIMETHYL 3,7,17 TRIOXO 2 OXACYCLOPENTA[A]PHENANTHREN 11 YL ACETATE; 8 [4 (1 AMINOCYCLOBUTYL)PHENYL] 9 PHENYL 1,2,4 TRIAZOLO[3,4 F][1,6]NAPHTHYRIDIN 3(2H) ONE; AFATINIB; ANTINEOPLASTIC AGENT; BIOLOGICAL MARKER; BRIVANIB; BUPARLISIB; BYL 719; CRIZOTINIB; DABRAFENIB; DACOMITINIB; DASATINIB; ERLOTINIB; GEFITINIB; LAPATINIB; LDK 378; LENVATINIB; MOLECULAR MARKER; ONARTUZUMAB; PAZOPANIB; PERIFOSINE; PF 04691502; SELUMETINIB; SUNITINIB; TIVANTINIB; TRAMETINIB; UNCLASSIFIED DRUG; UNINDEXED DRUG; XL 147; XL 765;

CANCER TISSUE; DRUG DEVELOPMENT; DRUG SCREENING; DRUG TARGETING; GENE TECHNOLOGY; GENETIC PROCEDURES; HUMAN; LUNG CARCINOGENESIS; LUNG NON SMALL CELL CANCER; MOLECULAR PROFILING; MOLECULARLY TARGETED THERAPY; NEXT GENERATION SEQUENCING; PRIORITY JOURNAL; REVIEW; TURNAROUND TIME;

BIOPSY; CARCINOMA, NON-SMALL-CELL LUNG; CLINICAL TRIALS AS TOPIC; DNA MUTATIONAL ANALYSIS; GENE EXPRESSION PROFILING; HUMANS; LUNG; LUNG NEOPLASMS; MOLECULAR TARGETED THERAPY; PROTEOME; TISSUE ARRAY ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 84874575400     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mds478     Document Type: Review

References (64)

1. Macconaill LE, Van Hummelen P, Meyerson M et al. Clinical implementation of comprehensive strategies to characterize cancer genomes: opportunities and challenges. Cancer Discov 2011; 1: 297.
2. Von Hoff DD, Stephenson JJ, Jr, Rosen P et al. Pilot study using molecular profiling of patients' tumors to find potential targets and select treatments for their refractory cancers. J Clin Oncol 2010; 28: 4877-4883.
3. Tsimberidou AM, Iskander NG, Hong DS et al. Personalized medicine in a phase I clinical trials program: The M. D. Anderson Cancer Center Initiative. J Clin Oncol 2011; 29 (suppl) (Abstr CRA2500).
4. Sequist LV, Heist RS, Shaw AT et al. Implementing multiplexed genotyping of non-small-cell lung cancers into routine clinical practice. Ann Oncol 2011; 22:2616-2624
5. Kris MG, Lau C, Ang D et al. Initial results of LC-MAP: An institutional program to routinely profile tumor specimens for the presence of mutations in targetable pathways in all patients with lung adenocarcinoma. J Clin Oncol 2010; 28 (suppl) (Abstr 7009).
6. Ortiz TM, Joshi VA, Heon S et al. The introduction of systematic genomic testing for patients with non-small cell lung cancer (NSCLC) at Dana-Farber Cancer Institute (DFCI). J Clin Oncol 2011; 29 (suppl) (Abstr 7517).
7. Kim ES, Herbst RS, Wistuba II et al. The BATTLE trial: personalizing therapy for lung cancer. Cancer Discov 2011; 1: 44-53.
8. Reck M, Hermes A, Tan EH et al. Tissue sampling in lung cancer: a review in light of the MERIT experience. Lung Cancer 2011; 74: 1-6.
9. Solomon SB, Zakowski MF, Pao W et al. Core needle lung biopsy specimens: adequacy for EGFR and KRAS mutational analysis. Am J Roentgenol 2010; 194: 266-269.
10. Cheung YC, Chang JW, Hsieh JJ et al. Adequacy and complications of computed tomography-guided core needle biopsy on non-small cell lung cancers for epidermal growth factor receptor mutations demonstration: 18-gauge or 20- gauge biopsy needle. Lung Cancer 2010; 67: 166-169.
11. Gill RR, Heon S, Yeap BY et al. Genomic profiling of non-small cell lung cancer (NSCLC) for personalized targeted therapy using CT-guided transthoracic needle biopsy (TTNB). J Clin Oncol 2012; 30 (suppl) (Abstr 10592).
12. Garcia-Olive I, Monso E, Andreo F et al. Endobronchial ultrasound-guided transbronchial needle aspiration for identifying EGFR mutations. Eur Respir J 2010; 35: 391-395
13. Maheswaran S, Sequist LV, Nagrath S et al. Detection of mutations in EGFR in circulating lung-cancer cells. N Engl J Med 2008; 359: 366-377.
14. Leary RJ, Kinde I, Diehl F et al. Development of personalized tumor biomarkers using massively parallel sequencing. Sci Transl Med 2010; 2: 20ra4.
15. Rekhtman N, Brandt SM, Sigel CS et al. Suitability of thoracic cytology for new therapeutic paradigms in non-small cell lung carcinoma: high accuracy of tumor subtyping and feasibility of EGFR and KRAS molecular testing. J Thorac Oncol 2011; 6: 451-458.
16. Smouse JH, Cibas ES, Janne PA et al. EGFR mutations are detected comparably in cytologic and surgical pathology specimens of nonsmall cell lung cancer. Cancer 2009; 117: 67-72.
17. Travis WD, Rekhtman N. Pathological diagnosis and classification of lung cancer in small biopsies and cytology: strategic management of tissue for molecular testing. Semin Respir Crit Care Med 2011; 32: 22-31.
18. Williams C, Ponten F, Moberg C et al. A high frequency of sequence alterations is due to formalin fixation of archival specimens. Am J Pathol 1999; 155: 1467-1471.
19. Fischer AH, Cibas ES, Howell LP et al. Role of cytology in the management of non-small-cell lung cancer. J Clin Oncol 2011; 29: 3331-3332.
20. CAP/IASLC/AMP Lung Cancer Biomarkers Guideline draft recommendations. http://www.cap.org/apps/docs/membership/transformation/new/ lung_public_comment_supporting_materials.pdf (11 June 2012, date last accessed).
21. Sequist LV, Waltman BA, Dias-Santagata D et al. Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors. Sci Transl Med 2011; 3: 75ra26.
22. Peppercorn J, Shapira I, Collyar D et al. Ethics of mandatory research biopsy for correlative end points within clinical trials in oncology. J Clin Oncol 2010; 28: 2635-2640.
23. Thomas RK, Baker AC, Debiasi RM et al. High-throughput oncogene mutation profiling in human cancer. Nat Genet 2007; 39: 347-351.
24. Dias-Santagata D, Akhavanfard S, David SS et al. Rapid targeted mutational analysis of human tumours: a clinical platform to guide personalized cancer medicine. Embo Mol Med 2010; 2: 146-158.
25. Su Z, Dias-Santagata D, Duke M et al. A platform for rapid detection of multiple oncogenic mutations with relevance to targeted therapy in non-small-cell lung cancer. J Mol Diagn 2011; 13: 74-84.
26. Metzker ML. Sequencing technologies - the next generation. Nat Rev Genet 2010; 11: 31-46.
27. Meyerson M, Gabriel S, Getz G. Advances in understanding cancer genomes through second-generation sequencing. Nat Rev Genet 2010; 11: 685-696.
28. Shaw AT, Solomon B, Kenudson MM. Crizotinib and testing for ALK. J Natl Compr Canc Netw 2011; 9: 1335-1341.
29. Mino-Kenudson M, Chirieac LR, Law K et al. A novel, highly sensitive antibody allows for the routine detection of ALK-rearranged lung adenocarcinomas by standard immunohistochemistry. Clin Cancer Res 2010; 16: 1561-1571.
30. Paik JH, Choe G, Kim H et al. Screening of anaplastic lymphoma kinase rearrangement by immunohistochemistry in non-small cell lung cancer correlation with fluorescence in situ hybridization. J Thorac Oncol 2011; 6: 466-472.
31. Yi ES, Boland JM, Maleszewski JJ et al. Correlation of IHC and FISH for ALK gene rearrangement in non-small cell lung carcinoma: IHC score algorithm for FISH. J Thorac Oncol 2011; 6: 459-465.
32. Williams PM, Lively TG, Jessup JM et al Bridging the gap: moving predictive and prognostic assays from research to clinical use. Clin Cancer Res 2012; 18: 1531-1539.
33. Wagle N, Berger MF, Davis MJ et al. High-throughput detection of actionable genomic alterations in clinical tumor samples by targeted, massively parallel sequencing. Cancer Discov 2012; 18:
34. Wen Y-Y, Fang E, Li Y et al. The efficacy of targeted next-generation sequencing for detection of clinically actionable mutations in cancer. J Clin Oncol 2012; 30 (suppl) (Abstr 10598).
35. Taillade L, Penault-Llorca F, Boulet T et al. Immunohistochemichal expression of biomarkers: a comparative study between diagnostic bronchial biopsies and surgical specimens of non-small-cell lung cancer. Ann Oncol 2007; 18: 1043-1050.
36. Yatabe Y, Matsuo K, Mitsudomi T. Heterogeneous distribution of EGFR mutations is extremely rare in lung adenocarcinoma. J Clin Oncol 2011; 29: 2972-2977.
37. Schmid K, Oehl N, Wrba F et al. EGFR/KRAS/BRAF mutations in primary lung adenocarcinomas and corresponding locoregional lymph node metastases. Clin Cancer Res 2009; 15: 4554-4560.
38. Park S, Holmes-Tisch AJ, Cho EY et al. Discordance of molecular biomarkers associated with epidermal growth factor receptor pathway between primary tumors and lymph node metastasis in non-small cell lung cancer. J Thorac Oncol 2009; 4: 809-815.
39. Sun LN, Zhang QA, Luan HL et al. Comparison of KRAS and EGFR gene status between primary non-small cell lung cancer and local lymph node metastases: implications for clinical practice. J Exp Clin Canc Res 2011; 30: 30.
40. Kalikaki A, Koutsopoulos A, Trypaki M et al. Comparison of EGFR and K-RAS gene status between primary tumours and corresponding metastases in NSCLC. Br J Cancer. 2008; 99: 923-929.
41. Gow CH, Chang YL, Hsu YC et al. Comparison of epidermal growth factor receptor mutations between primary and corresponding metastatic tumors in tyrosine kinase inhibitor-naive non-small-cell lung cancer. Ann Oncol 2009; 20: 696-702.
42. Cortot AB, Italiano A, Burel-Vandenbos F et al. KRAS mutation status in primary nonsmall cell lung cancer and matched metastases. Cancer 2010; 116: 2682-2687.
43. Chena ZY, Zhonga WZ, Zhanga XC et al. EGFR mutation heterogeneity and the mixed response to EGFR tyrosine kinase inhibitors of lung adenocarcinomas. Oncologist 2012; 17: 978-985.
44. Polyak K, Shipitsin M, Campbell-Marrotta L et al Breast tumor heterogeneity: causes and consequences. Breast Cancer Res 2009; 11(Suppl 1): S18.
45. Taniguchi K, Okami J, Kodama K et al. Intratumor heterogeneity of epidermal growth factor receptor mutations in lung cancer and its correlation to the response to gefitinib. Cancer Sci 2008; 99: 929-935.
46. Turke AB, Zejnullahu K, Wu YL et al. Preexistence and clonal selection of MET amplification in EGFR mutant NSCLC. Cancer Cell 2010; 17: 77-88.
47. Su KY, Chen HY, Li KC et al. Pretreatment epidermal growth factor receptor (EGFR) T790M mutation predicts shorter EGFR tyrosine kinase inhibitor response duration in patients with non-small-cell lung cancer. J Clin Oncol 2012; 30: 433-440.
48. Giaccone G, Herbst RS, Manegold C et al. Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial-INTACT 1. J Clin Oncol 2004; 22: 777-784.
49. Herbst RS, Giaccone G, Schiller JH et al. Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial-INTACT 2. J Clin Oncol 2004; 22: 785-794.
50. Herbst RS, Prager D, Hermann R et al. TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer. J Clin Oncol 2005; 23: 5892-5899.
51. Thatcher N, Chang A, Parikh P et al. Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer). Lancet 2005; 366: 1527-1537.
52. Gatzemeier U, Pluzanska A, Szczesna A et al. Phase III study of erlotinib in combination with cisplatin and gemcitabine in advanced non-small-cell lung cancer: the Tarceva Lung Cancer Investigation Trial. J Clin Oncol 2007; 25: 1545-1552.
53. Kwak EL, Bang YJ, Camidge DR et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med 2010; 363: 1693-1703.
54. Crinó L, Kim D, Riely GJ et al Initial phase II results with crizotinib in advanced ALK-positive non-small cell lung cancer (NSCLC): PROFILE 1005. J Clin Oncol 2011; 29 (suppl) (Abstr 7514).
55. Yap TA, Sandhu SK, Workman P et al. Envisioning the future of early anticancer drug development. Nat Rev Cancer 2010; 10: 514-523.
56. Simon R. Optimal two-stage designs for phase II clinical trials. Control Clin Trials 1989; 10: 1-10.
57. Zhou X, Liu S, Kim ES et al. Bayesian adaptive design for targeted therapy development in lung cancer-a step toward personalized medicine. Clin Trials 2008; 5: 181-193.
58. Kris MG, Johnson BE, Kwiatkowski DJ et al. Identification of driver mutations in tumor specimens from 1,000 patients with lung adenocarcinoma: The NCI's Lung Cancer Mutation Consortium (LCMC). J Clin Oncol 2011; 29 (abstr) (Abstr CRA7506).
59. FDA prescribing information Xalkori (crizotinib). http://www.accessdata.fda.gov/ drugsatfda_docs/label/2011/202570s000lbl.pdf. Accessed June 11, 2012.
60. Bergethon K, Shaw AT, Ignatius Ou SH et al. ROS1 rearrangements define a unique molecular class of lung cancers. J Clin Oncol 2012; 30: 863-870.
61. Freidlin B, Jiang WY, Simon R. The cross-validated adaptive signature design. Clin Cancer Res 2010; 16: 691-698.
62. Freidlin B, Simon R. Adaptive signature design: an adaptive clinical trial design for generating and prospectively testing a gene expression signature for sensitive patients. Clin Canc Res 2005; 11: 7872-7878.
63. Miller FG, Joffe S. Equipoise and the dilemma of randomized clinical trials. N Engl J Med 2011; 364: 476-80.
64. Sharma MR, Schilsky RL. Role of randomized phase III trials in an era of effective targeted therapies. Nat Rev Clin Oncol 2011; 9: 208-214.